Figure 5.

Kaplan–Meier curves for overall survival and progression-free survival in the intention-to-treat population. The median follow-up for overall survival in the ipilimumab (Ipi)-plus-glycop, 8.5 to 11.5); in the ipilimumab-alone group, the median follow-up was 27.8 months, and the median overall survival, 10.1 months (95% CI, 8.0, 13.8); and in the gp100-alone group, the median follow-up was 17.2 months, and the median overall survival, 6.4 months (95% CI, 5.5, 8.7). , censored; , censored